Cargando…
A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab
OBJECTIVE: Mepolizumab, a humanized anti-interleukin-5 monoclonal antibody, is effective for treating eosinophilic severe asthma. However, there is a need for more biomarkers that can predict the patient response to mepolizumab before starting therapy. This study aimed to identify a new biomarker in...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725639/ https://www.ncbi.nlm.nih.gov/pubmed/32713920 http://dx.doi.org/10.2169/internalmedicine.5159-20 |
_version_ | 1783620741031264256 |
---|---|
author | Suzukawa, Maho Ohshima, Nobuharu Tashimo, Hiroyuki Asari, Isao Kobayashi, Nobuyuki Shoji, Shunsuke Tohma, Shigeto Ohta, Ken |
author_facet | Suzukawa, Maho Ohshima, Nobuharu Tashimo, Hiroyuki Asari, Isao Kobayashi, Nobuyuki Shoji, Shunsuke Tohma, Shigeto Ohta, Ken |
author_sort | Suzukawa, Maho |
collection | PubMed |
description | OBJECTIVE: Mepolizumab, a humanized anti-interleukin-5 monoclonal antibody, is effective for treating eosinophilic severe asthma. However, there is a need for more biomarkers that can predict the patient response to mepolizumab before starting therapy. This study aimed to identify a new biomarker in the serum that is able to accurately predict the responsiveness to mepolizumab. METHODS: This study enrolled 11 patients who had all been diagnosed with severe eosinophilic asthma and were then administered mepolizumab every 4 weeks for at least 4 months. Blood samples were collected, and pulmonary function tests and questionnaires were administered at baseline and after 4, 8 and 16 weeks of treatment. The response to mepolizumab was then assessed based on the difference in the Asthma Quality of Life Questionnaire (AQLQ) score after 16 weeks of mepolizumab therapy compared with that at baseline. Patients with an increase in the AQLQ score of more than 0.5 were defined as responders. The cytokine levels in the blood were measured by LUMINEX 200 and ELISA. RESULTS: There were 6 responders and 5 non-responders. The responders showed a significantly lower serum level of chemokine (C-C motif) ligand 4/macrophage inflammatory protein-1β (CCL4/MIP-1β) at baseline compared to the non-responders. Receiver operating characteristic curves to distinguish responders from non-responders using the baseline serum CCL4/MIP-1β level showed a good area under the curve of 0.9. The non-responders showed a significant increase in the level of CCL4/MIP-1β after 4 weeks compared to the baseline. CONCLUSION: A low baseline serum CCL4/MIP-1β level may be useful for predicting a good mepolizumab response in severe eosinophilic asthma. |
format | Online Article Text |
id | pubmed-7725639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-77256392020-12-21 A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab Suzukawa, Maho Ohshima, Nobuharu Tashimo, Hiroyuki Asari, Isao Kobayashi, Nobuyuki Shoji, Shunsuke Tohma, Shigeto Ohta, Ken Intern Med Original Article OBJECTIVE: Mepolizumab, a humanized anti-interleukin-5 monoclonal antibody, is effective for treating eosinophilic severe asthma. However, there is a need for more biomarkers that can predict the patient response to mepolizumab before starting therapy. This study aimed to identify a new biomarker in the serum that is able to accurately predict the responsiveness to mepolizumab. METHODS: This study enrolled 11 patients who had all been diagnosed with severe eosinophilic asthma and were then administered mepolizumab every 4 weeks for at least 4 months. Blood samples were collected, and pulmonary function tests and questionnaires were administered at baseline and after 4, 8 and 16 weeks of treatment. The response to mepolizumab was then assessed based on the difference in the Asthma Quality of Life Questionnaire (AQLQ) score after 16 weeks of mepolizumab therapy compared with that at baseline. Patients with an increase in the AQLQ score of more than 0.5 were defined as responders. The cytokine levels in the blood were measured by LUMINEX 200 and ELISA. RESULTS: There were 6 responders and 5 non-responders. The responders showed a significantly lower serum level of chemokine (C-C motif) ligand 4/macrophage inflammatory protein-1β (CCL4/MIP-1β) at baseline compared to the non-responders. Receiver operating characteristic curves to distinguish responders from non-responders using the baseline serum CCL4/MIP-1β level showed a good area under the curve of 0.9. The non-responders showed a significant increase in the level of CCL4/MIP-1β after 4 weeks compared to the baseline. CONCLUSION: A low baseline serum CCL4/MIP-1β level may be useful for predicting a good mepolizumab response in severe eosinophilic asthma. The Japanese Society of Internal Medicine 2020-07-21 2020-11-15 /pmc/articles/PMC7725639/ /pubmed/32713920 http://dx.doi.org/10.2169/internalmedicine.5159-20 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Suzukawa, Maho Ohshima, Nobuharu Tashimo, Hiroyuki Asari, Isao Kobayashi, Nobuyuki Shoji, Shunsuke Tohma, Shigeto Ohta, Ken A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab |
title | A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab |
title_full | A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab |
title_fullStr | A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab |
title_full_unstemmed | A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab |
title_short | A Low Serum CCL4/MIP-1β Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab |
title_sort | low serum ccl4/mip-1β level may predict a severe asthmatic responsiveness to mepolizumab |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725639/ https://www.ncbi.nlm.nih.gov/pubmed/32713920 http://dx.doi.org/10.2169/internalmedicine.5159-20 |
work_keys_str_mv | AT suzukawamaho alowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab AT ohshimanobuharu alowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab AT tashimohiroyuki alowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab AT asariisao alowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab AT kobayashinobuyuki alowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab AT shojishunsuke alowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab AT tohmashigeto alowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab AT ohtaken alowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab AT suzukawamaho lowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab AT ohshimanobuharu lowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab AT tashimohiroyuki lowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab AT asariisao lowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab AT kobayashinobuyuki lowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab AT shojishunsuke lowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab AT tohmashigeto lowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab AT ohtaken lowserumccl4mip1blevelmaypredictasevereasthmaticresponsivenesstomepolizumab |